Brief: FDA Clears Appili Therapeutics To Expand Its Phase 2 Clinical Trial Of Favipiravir For The Potential Prevention Of Covid-19 At U.S. Long-Term Care Facilities

Appili Therapeutics

10/08/2020 14:29

Aug 10 (Reuters) - Appili Therapeutics Inc  APLI.V :
    * FDA CLEARS APPILI THERAPEUTICS TO EXPAND ITS PHASE 2
CLINICAL
TRIAL OF FAVIPIRAVIR FOR THE POTENTIAL PREVENTION OF COVID-19 AT
U.S. LONG-TERM CARE FACILITIES
    * APPILI THERAPEUTICS INC -  INTENDS TO ENROLL UP TO 760
PARTICIPANTS IN FAVIPIRAVIR PHASE 2 CLINICAL TRIAL ACROSS BOTH
U.S. AND IN CANADA

Source text for Eikon:  ID:nBw8g0WFRa 
Further company coverage:  APLI.V 

 ((Reuters.Briefs@thomsonreuters.com;))